TrialMuscle & nerve2023
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
Angela Genge et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
20 papers cite it
this papertrialcites it